The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae

International Journal of Infectious Diseases

Volumn 17, Issue 3, 2013, Pages

  Doi, Asako ^a   Shimada, Toshihiko ^b   Harada, Sohei ^c   Iwata, Kentaro ^d   Kamiya, Toru ^a  

^a RAKUWAKAI OTOWA HOSPITAL   (Japan)

^b Nara City Hospital   (Japan)

^c TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KOBE UNIVERSITY HOSPITAL   (Japan)

Author keywords

Carbapenem; Cefmetazole; Cephamycin; Extended spectrum beta lactamase (ESBL); Urinary tract infections

Indexed keywords

CARBAPENEM; CEFMETAZOLE; EXTENDED SPECTRUM BETA LACTAMASE;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; CLINICAL ARTICLE; DATA BASE; DRUG EFFICACY; ENTEROBACTERIACEAE; FEMALE; HUMAN; INCIDENCE; MALE; MEDICAL RECORD REVIEW; PYELONEPHRITIS; RETROSPECTIVE STUDY; TREATMENT DURATION; URINARY TRACT INFECTION; URINE CULTURE;

AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CARBAPENEMS; CEFMETAZOLE; CULTURE MEDIA; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PYELONEPHRITIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; URINE;

EID: 84874496374     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2012.09.010     Document Type: Article

References (33)

1. Pitout J.D., Laupland K.B. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008, 8:159-166.
2. Yamaguchi K., Ohno A., Ishii Y., Tateda K., Iwata M., Kanda M., et al. In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,919 clinical isolates obtained from 72 centers in 2007 (in Japanese). Jpn J Antibiot 2009, 62:346-370.
3. Suzuki S., Shibata N., Yamane K., Wachino J., Ito K., Arakawa Y. Change in the prevalence of extended-spectrum-beta-lactamase-producing Escherichia coli in Japan by clonal spread. J Antimicrob Chemother 2009, 63:72-79.
4. Chong Y., Yakushiji H., Ito Y., Kamimura T. Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a long-term study from Japan. Eur J Clin Microbiol Infect Dis 2011, 30:83-87.
5. Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement. M100-S20 2010, Clinical and Laboratory Standards Institute, CLSI, Wayne, PA.
6. Harada S., Ishii Y., Yamaguchi K. Extended-spectrum beta-lactamases: implications for the clinical laboratory and therapy. Korean J Lab Med 2008, 28:401-412.
7. Paterson D.L., Daveson K. Cefoxitin, cefotetan and other cephamycins (cefmetazole and flomoxef). Kucers' The use of antibiotics 2010, 301-310. Edward Arnold, London. M.L. Grayson (Ed.).
8. Paterson D.L., Bonomo R.A. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005, 18:657-686.
9. DHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 beta-lactamases. J Antimicrob Chemother 2007, 60:410-413.
10. Bradford P.A., Urban C., Mariano N., Projan S.J., Rahal J.J., Bush K. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997, 41:563-569.
11. Yamasaki K., Komatsu M., Abe N., Fukuda S., Miyamoto Y., Higuchi T., et al. Laboratory surveillance for prospective plasmid-mediated AmpC beta-lactamases in the Kinki region of Japan. J Clin Microbiol 2010, 48:3267-3273.
12. Lee C.H., Su L.H., Tang Y.F., Liu J.W. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates. J Antimicrob Chemother 2006, 58:1074-1077.
13. Rhee J.Y., Kwon K.T., Ki H.K., Shin S.Y., Jung D.S., Chung D.R., et al. Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the acute physiology and chronic health evaluation II scoring systems. Shock 2009, 31:146-150.
14. Performance standards for antimicrobial susceptibility testing. Twenty-first informational supplement. M100-S21 2011, Clinical and Laboratory Standards Institute, CLSI, Wayne, PA.
15. R foundation for Statistical Computing. Available at: (accessed January 11, 2012). http://www.r-project.org/.
16. Rodríguez-Baño J., Alcala J.C., Cisneros J.M., Grill F., Oliver A., Horcajada J.P., et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 2008, 168:1897-1902.
17. Ben-Ami R., Rodríguez-Baño J., Arslan H., Pitout J.D., Quentin C., Calbo E.S., et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009, 49:682-690.
18. Pitout J.D., Nordmann P., Laupland K.B., Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005, 56:52-59.
19. Marchaim D., Gottesman T., Schwartz O., Korem M., Maor Y., Rahav G., et al. National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2010, 54:5099-5104.
20. Cantón R., Coque T.M. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol 2006, 9:466-475.
21. Endimiani A., Luzzaro F., Perilli M., Lombardi G., Coll A., Tamborini A., et al. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis 2004, 38:243-251.
22. Paterson D.L., Ko W.C., Von Gottberg A., Mohapatra S., Casellas J.M., Goossens H., et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004, 39:31-37.
23. Falagas M.E., Kastoris A.C., Kapaskelis A.M., Karageorgopoulos D.E. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010, 10:43-50.
24. Senol S., Tasbakan M., Pullukcu H., Sipahi O.R., Sipahi H., Yamazhan T., et al. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection. J Chemother 2010, 22:355-357.
25. Pitout J.D. Infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 2010, 70:313-323.
26. Oteo J., Bautista V., Lara N., Cuevas O., Arroyo M., Fernández S., et al. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. J Antimicrob Chemother 2010, 65:2459-2463.
27. Schultsz C., Geerlings S. Plasmid-mediated resistance in Enterobacteriaceae: changing landscape and implications for therapy. Drugs 2012, 72:1-16.
28. Auer S., Wojna A., Hell M. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli. Antimicrob Agents Chemother 2010, 54:4006-4008.
29. Rodríguez-Baño J., Navarro M.D., Retamar P., Picón E., Pascual A. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012, 54:167-174.
30. Ripoll A., Baquero F., Novais â., Rodríguez-Domínguez M.J., Turrient M.C., Cantón R., et al. In vitro selection of variants resistant to beta-lactams plus beta-lactamase inhibitors in CTX-M beta-lactamases: predicting the in vivo scenario?. Antimicrob Agents Chemother 2011, 55:4530-4536.
31. Owens R.C. An overview of harms associated with beta-lactam antimicrobials: where do the carbapenems fit in?. Crit Care 2008, 12(Suppl 4):S3.
32. Thomson K.S., Moland E.S. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001, 45:3548-3554.
33. Zimhony O., Chmelnitsky I., Bardenstein R., Goland S., Hammer Muntz O., Navon Venezia S., et al. Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility. Antimicrob Agents Chemother 2006, 50:3179-3182.